Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 12/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 11/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 11/20 | 0.50 |
| ▸ | PTGIR | P43119 | 4/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.41 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.41 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5656945 | 0.83 | PTGIR (0.59) | ADRA2AADRA2BADRA2CPTGIRWDR5 | |
| SCHEMBL5657902 | 0.78 | KDM4E (0.56) | ADRA2AADRA2BADRA2CPTGIR | |
| SCHEMBL5656503 | 0.78 | ADRA2A (0.59) | ADRA2AADRA2BADRA2CPTGIRWDR5 | |
| SCHEMBL5658542 | 0.78 | PTGIR (0.51) | ADRA2AADRA2BADRA2CPTGIRWDR5 | |
| SCHEMBL5657340 | 0.78 | ADRA2A (0.58) | ADRA2AADRA2BADRA2CPTGIRWDR5 | |
| SCHEMBL5657241 | 0.77 | ADRA2A (0.60) | ADRA2AADRA2BADRA2CPTGIRWDR5 | |
| SCHEMBL5659119 | 0.76 | PTGIR (0.59) | ADRA2AADRA2BADRA2CPTGIR | |
| SCHEMBL5657415 | 0.76 | ADRA2A (0.59) | ADRA2AADRA2BADRA2CPTGIRWDR5 | |
| SCHEMBL5657222 | 0.76 | ADRA2A (0.59) | ADRA2AADRA2BADRA2CPTGIRWDR5 | |
| SCHEMBL5659779 | 0.76 | ADRA2A (0.59) | ADRA2AADRA2BADRA2CPTGIRWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279498-B2 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279498-B2 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279498-B2 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-6998414-B2 | Substituted arylamides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2006-02-14 | — | — | US | disclosed |
| US-20060004075-A1 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004075-A1 | Substituted aryl amides as IP antagonists | INSR, INSRR, GIPR | ADRA2A 90/4885ADRA2B 82/4885ADRA2C 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.